# 2025年11月8日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 癫痫治疗的长期管理：以象棋博弈类比抗癫痫药物的选择、调整与加用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201207](https://pubmed.ncbi.nlm.nih.gov/41201207)
**期刊：** Epilepsia
**PMID：** 41201207
**DOI：** 10.1111/epi.70005

### 第一部分 原文与翻译

**英文原标题：** Epilepsy treatment over time: The chess game analogy for choosing, adjusting, and adding antiseizure medications.

**英文摘要原文：**
Recurrent seizures have such a negative impact upon the lives of persons with epilepsy that their prevention is a constant preoccupation of neurologists. Despite the large number of antiseizure medications (ASMs) currently available and of publications on their putative efficacy, adverse effects, and order of preference to start treatment, there is very little information on how to manage treatment over time. Here, we propose the analogy of a chess game to encourage neurologists to develop strategic decisions at each point in time to correctly manage ASMs toward the best possible degree of seizure control. We leverage that the strategy of the chess player must be adapted to each move of the opponent, to emphasize the need to individualize the treatment of epileptic seizures according to variations in response to ASMs that occur over time. The chess player calculates the best move at each point in the chess game just as the neurologist draws upon their knowledge and experience to select the best ASM regimen for a given patient and adjust it based on their "gestalt" of the patient's response to each treatment change. This gestalt, however, is firmly grounded in rational, flexible adaptations to ASM treatment protocols. Strategic decision-making in several epilepsy scenarios is given to illustrate the utility of the chess analogy.

**中文摘要译文：**
复发性癫痫发作对癫痫患者的生活有极大的负面影响，因此预防其发作是神经科医生持续关注的重点。尽管目前已有大量的抗癫痫药物（ASMs）可用，且关于其假定疗效、不良反应和初始治疗的优选顺序已有诸多发表，但关于如何长期管理治疗的信息却非常有限。在此，我们提出象棋博弈的类比，旨在鼓励神经科医生在每个时间点上制定战略性决策，以正确地管理ASMs，从而达到最佳的癫痫发作控制程度。我们借鉴了棋手策略必须根据对手的每一步棋进行调整的特点，以强调根据患者对ASMs治疗反应随时间发生的变化，来个体化治疗癫痫发作的必要性。正如棋手在棋局的每一步计算最佳走法一样，神经科医生也利用其知识和经验为特定患者选择最佳的ASM方案，并根据他们对患者每次治疗变化的“完形”感知来调整方案。然而，这种“完形”感知是牢固地建立在对ASM治疗方案进行合理、灵活调整的基础之上的。文中列举了数个癫痫场景中的战略决策过程，以阐明象棋类比的实用性。

### 第二部分 AI 大师评价

本文创新性地提出“象棋博弈”类比，旨在为神经科医生长期管理癫痫治疗提供一个概念框架。作者通过将抗癫痫药物（ASM）的选择与调整比作棋局中的策略决策，强调了根据患者反应动态调整治疗方案的个体化重要性。该文的核心价值在于提供了一个直观且深刻的思维模型，倡导医生超越固定的治疗指南，进行更具战略性和灵活性的临床实践。尽管这是一篇观点性文章而非实证研究，但它对启发临床思维、改善癫痫长期治疗策略具有重要的教学和实践指导意义。

---

## 2. 卒中后癫痫患者的抗惊厥药物治疗：一项生存分析研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41200822](https://pubmed.ncbi.nlm.nih.gov/41200822)
**期刊：** Epilepsia
**PMID：** 41200822
**DOI：** 10.1111/epi.18706

### 第一部分 原文与翻译

**英文原标题：** Anti-seizure medications in patients with post-stroke epilepsy: A survival analysis study.

**英文摘要原文：**
OBJECTIVE: The role of antiseizure medications (ASMs) in patients with post-stroke epilepsy (PSE) is still debated. Although a few studies have compared the efficacy of different ASMs on mortality in patients with PSE, overall evidence on the impact of ASM use on survival is limited. This study aimed to evaluate the association between ASM use and all-cause mortality in patients with PSE.

METHODS: A cohort study was conducted using health care administrative database of Health Protection Agency of Bergamo (Italy). Individuals with a diagnosis of stroke followed by epilepsy onset between January 1, 2014 and December 31, 2017 were included. The date of epilepsy was considered as Index date (ID). Patients were followed from the ID until death, disenrollment, or end of follow-up, whichever occurred first. Exposure to ASMs was defined as at least one dispensing within 30 days of the ID; patients without ASM dispensing during this period were considered non-exposed. All-cause mortality was analyzed using Cox proportional hazards models, with non-exposure as the reference. Two analytical approaches were adopted: an intention-to-treat analysis and a time-dependent analysis.

RESULTS: A total of 145 patients met the inclusion criteria: 107 ASM users and 38 non-users. In the intention-to-treat analysis, ASM use was associated with a lower risk of all-cause mortality (adjusted hazard ratio [HR]: 0.56; 95% confidence interval [CI]: 0.33-0.95). Consistent findings were observed in the time-dependent analysis (adjusted HR: 0.39; 95% CI: 0.23-0.65). The sensitivity analyses confirmed the robustness of the results.

SIGNIFICANCE: In this population-based cohort study, ASM use in patients with PSE was associated with a significantly reduced risk of all-cause mortality compared to non-use. These findings support the hypothesis that ASM treatment might be associated with positive effect in this high-risk population.

**中文摘要译文：**
目的：抗惊厥药物（ASMs）在卒中后癫痫（PSE）患者中的作用仍有争议。尽管有少数研究比较了不同ASM对PSE患者死亡率的疗效，但关于ASM使用对生存影响的总体证据有限。本研究旨在评估PSE患者使用ASM与全因死亡率之间的关联。

方法：本研究利用意大利贝加莫健康保护局的医疗行政数据库进行了一项队列研究。研究纳入了在2014年1月1日至2017年12月31日期间诊断为卒中并随后发生癫痫的个体。癫痫发作日期被视为指数日期（ID）。患者从指数日期起接受随访，直至死亡、退出研究或随访结束（以先发生者为准）。ASM暴露定义为在指数日期后30天内至少有一次药物配发；在此期间没有ASM配发的患者被视为未暴露组。采用Cox比例风险模型分析全因死亡率，以未暴露组为参照。研究采用了两种分析方法：意向性治疗分析和时间依赖性分析。

结果：共有145名患者符合纳入标准：107名ASM使用者和38名非使用者。在意向性治疗分析中，使用ASM与较低的全因死亡率风险相关（调整后风险比[HR]：0.56；95%置信区间[CI]：0.33-0.95）。在时间依赖性分析中观察到了一致的结果（调整后HR：0.39；95% CI：0.23-0.65）。敏感性分析证实了结果的稳健性。

意义：在这项基于人群的队列研究中，与不使用ASM相比，PSE患者使用ASM与全因死亡率风险的显著降低相关。这些发现支持了ASM治疗可能对这一高风险人群产生积极影响的假说。

### 第二部分 AI 大师评价

本研究通过一项基于人群的队列研究，旨在探讨卒中后癫痫（PSE）患者使用抗惊厥药物（ASM）与全因死亡率之间的关联。其关键发现是，无论采用意向性治疗分析还是时间依赖性分析，ASM的使用均与全因死亡风险的显著降低相关。这项研究为ASM在高风险的PSE患者中的应用提供了重要的生存获益证据，对临床决策具有参考价值。然而，作为一项观察性研究，其结论尚需前瞻性随机对照试验的进一步验证以明确因果关系。

---

## 3. 癫痫专科医生分布的地理异质性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41197108](https://pubmed.ncbi.nlm.nih.gov/41197108)
**期刊：** Neurology
**PMID：** 41197108
**DOI：** 10.1212/WNL.0000000000214361

### 第一部分 原文与翻译

**英文原标题：** Geographic Heterogeneity in Epilepsy Specialist Distribution.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究的核心目的在于揭示癫痫专科医生在地理分布上的不均衡性。尽管缺乏摘要，但从标题推断，研究可能通过分析特定区域内的医疗资源数据，绘制出癫痫专家的执业地点分布图，并量化其异质性。其关键发现可能在于明确指出了服务资源过剩与严重不足的地区，凸显了癫痫患者在获取专业化诊疗服务方面存在巨大的地理障碍。这项研究对于优化医疗资源配置、指导卫生政策制定以及推动远程医疗服务在资源匮乏地区的应用具有重要的现实意义。

---

## 4. 局灶性皮质发育不良相关癫痫患儿执行功能障碍的临床、影像学及病理学关联

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41197105](https://pubmed.ncbi.nlm.nih.gov/41197105)
**期刊：** Neurology
**PMID：** 41197105
**DOI：** 10.1212/WNL.0000000000214352

### 第一部分 原文与翻译

**英文原标题：** Clinical, Radiologic, and Pathologic Associations of Executive Dysfunction in Children With Focal Cortical Dysplasia-Related Epilepsy.

**英文摘要原文：**
BACKGROUND AND OBJECTIVE: Executive dysfunction (ExD) is a common comorbidity of focal epilepsy. Focal cortical dysplasia (FCD) is the most common lesional cause of epilepsy in children. We aimed to investigate clinical, etiologic (pathology), and anatomic vs functional network associations with ExD in FCD-related epilepsy. FCD lesion-network interactions may underlie ExD. The primary analysis was to evaluate whether FCD colocalization to frontoparietal control network or attention networks is associated with ExD. We also evaluated whether FCD type I pathology is associated with ExD because it is reported to be associated with worse intellectual function.

METHODS: Patients with FCD were included from retrospective surgical/radiologic databases at Children's National Hospital from January 2000 to January 2022 if they had preoperative neuropsychological testing. FCD colocalization to the Yeo 7-network atlas was determined. Clinical, radiologic, and pathologic factors were evaluated for association with ExD. The primary outcome measure was ExD measured categorically (ExD/Not ExD) and linearly (Behavior Rating Inventory of Executive Function [BRIEF]-Global Executive Composite [GEC] T-score).

RESULTS: Ninety-three patients with FCD (45% female) had preoperative BRIEF-GEC T-scores sampled at 11.4 years (SD 4.5 years). Control network colocalization (odds ratio [OR] 3.6, 95% CI 0.94-13.9,  < 0.05) and FCD type I (OR 4.45, 95% CI 1.39-14.3,  = 0.009) are associated with ExD (BRIEF-GEC T-score ≥65). Control network colocalization is associated with Cognitive Regulation Index (mean difference 8.3, 95% CI 0.7-15.9,  = 0.03) and Plan/Organize subscale (8.4, 95% CI 0.9-16.0,  = 0.028). FCD type I is associated with BRIEF-GEC T-score (8.3, 95% CI 2.3-14.2,  = 0.007), Cognitive Regulation Index (7.1, 95% CI 1.2-13.1,  = 0.019), Working Memory (7.4, 95% CI 1.2-13.6,  = 0.021), Plan/Organize (6.0, 95% CI 0.21-11.8,  = 0.042), Shift (8.1, 95% CI 1.6-14.7,  = 0.015), and Emotional Control (8.5, 95% CI 2.5-14.5,  = 0.006) subscales. These findings were not related to Full Scale IQ. FCD colocalization to attentional network (dorsal or ventral), lobar location, or age seizure onset was not associated with ExD.

DISCUSSION: These data demonstrate the importance of lesion-network interaction in neuropsychological comorbidity (ExD) in focal epilepsy, unrelated to lesion size or lobar location. FCD colocalization to the Frontoparietal Control network is associated with ExD in a heterogeneous cohort of FCD-related epilepsy. A network-level structure-function correlation is suggested as the most affected processes of cognitive regulation (e.g., planning/organization) are domains regulated by this network. This work contributes toward a more unified theory of focal epilepsy, by beginning to explain common neuropsychological deficits seen across the epilepsies by cortical lesion-network interaction and regardless of lobar location.

**中文摘要译文：**
背景与目的：执行功能障碍（ExD）是局灶性癫痫常见的共患病。局灶性皮质发育不良（FCD）是儿童癫痫最常见的病灶性原因。我们旨在探究FCD相关癫痫中，ExD与临床、病因（病理学）以及解剖与功能网络之间的关联。FCD病灶-网络交互作用可能是ExD的基础。主要分析旨在评估FCD病灶与额顶叶控制网络或注意网络的共定位是否与ExD相关。我们还评估了I型FCD病理是否与ExD相关，因为据报道该类型与较差的智力功能有关。

方法：本研究从国家儿童医院2000年1月至2022年1月的追溯性外科/影像学数据库中纳入了术前接受过神经心理学测试的FCD患者。通过Yeo 7网络图谱确定了FCD病灶的共定位情况。评估了临床、影像学和病理学因素与ExD的关联。主要结局指标是ExD，通过分类（ExD/非ExD）和线性（执行功能行为评定量表[BRIEF]-总体执行综合[GEC] T分数）方式进行衡量。

结果：93名FCD患者（45%为女性）在平均11.4岁（标准差4.5岁）时接受了术前BRIEF-GEC T分数检测。病灶与控制网络的共定位（比值比[OR] 3.6, 95% CI 0.94-13.9, p < 0.05）和I型FCD（OR 4.45, 95% CI 1.39-14.3, p = 0.009）与ExD（BRIEF-GEC T分数≥65）相关。病灶与控制网络的共定位与认知调节指数（均数差8.3, 95% CI 0.7-15.9, p = 0.03）和计划/组织分量表（8.4, 95% CI 0.9-16.0, p = 0.028）相关。I型FCD与BRIEF-GEC T分数（8.3, 95% CI 2.3-14.2, p = 0.007）、认知调节指数（7.1, 95% CI 1.2-13.1, p = 0.019）、工作记忆（7.4, 95% CI 1.2-13.6, p = 0.021）、计划/组织（6.0, 95% CI 0.21-11.8, p = 0.042）、转换（8.1, 95% CI 1.6-14.7, p = 0.015）和情绪控制（8.5, 95% CI 2.5-14.5, p = 0.006）等分量表相关。这些发现与全量表智商无关。FCD病灶与注意网络（背侧或腹侧）的共定位、脑叶位置或癫痫发作年龄与ExD无关。

讨论：这些数据证明了病灶-网络交互作用在局灶性癫痫的神经心理学共病（ExD）中的重要性，且这种作用与病灶大小或脑叶位置无关。在一个FCD相关癫痫的异质性队列中，FCD病灶与额顶叶控制网络的共定位与ExD相关。研究提示存在网络层面的结构-功能关联，因为受影响最严重的认知调节过程（如计划/组织能力）正是由该网络调控的领域。这项工作通过皮质病灶-网络交互作用，开始解释各种癫痫中常见的神经心理学缺陷，且不受脑叶位置影响，从而为建立一个更统一的局灶性癫痫理论做出了贡献。

### 第二部分 AI 大师评价

本研究旨在通过回顾性分析93名局灶性皮质发育不良（FCD）相关癫痫患儿的临床、病理及影像数据，探讨执行功能障碍（ExD）与病灶-脑功能网络交互作用之间的关系。研究的核心发现是，当FCD病灶与额顶叶控制网络共定位或病理类型为I型时，患儿出现ExD的风险显著增高，而这种关联独立于传统的病灶脑叶位置或大小。该研究的创新之处在于超越了“病灶定位决定功能”的传统观念，揭示了病灶对功能网络的扰动是导致认知共病的关键机制。这为理解和预测癫痫患者的认知障碍提供了全新的网络视角，对未来的临床评估和干预策略具有重要指导价值。

---

## 5. 儿童多发性硬化症中，将注射型疾病修正疗法转换为口服或输注型疗法与继续使用其他注射型疗法的真实世界有效性比较

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41195640](https://pubmed.ncbi.nlm.nih.gov/41195640)
**期刊：** Annals of neurology
**PMID：** 41195640
**DOI：** 10.1002/ana.78086

### 第一部分 原文与翻译

**英文原标题：** Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis.

**英文摘要原文：**
OBJECTIVE: To assess real-world effectiveness of switching disease-modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity.

METHODS: Of 2615 pediatric-onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders.

RESULTS: A total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety-three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52-1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20-0.57; rate ratio: 0.38, 95% CI = 0.21-0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09-0.37; rate ratio: 0.21, 95% CI = 0.10-0.44) (p < 0.001). Adjusted number needed to treat in person-years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03-8.69) and infusion over injectable 1.43 (95% CI = 1.00-3.88).

INTERPRETATION: Switching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long-term safety data are required. ANN NEUROL 2025.

**中文摘要译文：**
目的：评估在儿童多发性硬化（MS）和临床孤立综合征（CIS）患者中，对于初始接受平台注射型药物治疗的患者，转换疾病修正疗法（DMT）对疾病活动的真实世界有效性。

方法：本研究分析了来自美国儿童多发性硬化中心网络的12家诊所的2615名儿童期起病的脱髓鞘疾病患者数据。研究对象为确诊MS/CIS、初始接受平台注射型药物治疗，后转换为另一类平台注射型、口服或输注型DMT的患者。复发率采用负二项回归模型进行建模，并对预先识别的混杂因素进行了校正。

结果：共有212名儿童在18岁前转换了DMT（67%为女性，95%为MS）。其中，93名患者从注射型转换为另一种注射型，76名从注射型转换为口服型，43名从注射型转换为输注型。转换为口服或输注型疗法的患者在起病时（注射型12.3岁，口服型13.5岁，输注型14.2岁）和转换治疗时（注射型14.6岁，口服型16.0岁，输注型15.7岁）的年龄较大。转换为输注型DMT的患者更可能存在强化病灶（注射型45%，口服型28%，输注型67%）。与继续使用注射型疗法的患者（年化复发率[ARR] = 0.88, 95%置信区间[CI] = 0.52-1.48）相比，从注射型转换为口服型（ARR = 0.34, 95% CI = 0.20-0.57；比率比：0.38, 95% CI = 0.21-0.69）和从注射型转换为输注型（ARR = 0.18, 95% CI = 0.09-0.37；比率比：0.21, 95% CI = 0.10-0.44）的患者复发率更低（p < 0.001）。校正后，为预防1例复发，使用口服疗法替代注射疗法所需治疗的人年数为1.84（95% CI = 1.03-8.69），而使用输注疗法替代注射疗法为1.43（95% CI = 1.00-3.88）。

结论：在儿童MS患者中，与继续使用其他平台注射型DMT相比，从平台注射型DMT转换为口服或输注型DMT能带来更好的疾病控制效果。仍需长期的安全性数据。

### 第二部分 AI 大师评价

本研究基于美国多中心真实世界数据，旨在比较儿童多发性硬化症患者从平台注射型疾病修正疗法（DMT）转换至口服、输注疗法或其他注射型疗法的有效性。研究采用负二项回归模型分析复发率，其关键发现是，与换用其他注射型药物相比，升级为口服或输注疗法能显著降低年化复发率。这项研究为儿童MS患者的二线治疗选择提供了重要的临床证据，强调了在初始治疗效果不佳时，及时升级至更高效力疗法的价值，但其长期安全性仍需进一步关注。

---

## 6. 父母参与干预对患有慢性病的儿童和青少年生活质量及健康结局的影响：一项系统综述和荟萃分析。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41193782](https://pubmed.ncbi.nlm.nih.gov/41193782)
**期刊：** European journal of pediatrics
**PMID：** 41193782
**DOI：** 10.1007/s00431-025-06590-y

### 第一部分 原文与翻译

**英文原标题：** The effect of parental involvement intervention on quality of life and health outcomes among children and adolescents with chronic illness: a systematic review and meta-analysis.

**英文摘要原文：**
UNLABELLED: The aim of this study is to synthesize evidence from randomized controlled (RCTs) and quasi-experimental studies evaluating the effects of parental involvement interventions on quality of life and health outcomes among children and adolescents with chronic illness. Two independent reviewers screened studies according to predefined inclusion criteria across six databases (PubMed/MEDLINE, Scopus, ScienceDirect, Cochrane Library, and Embase). Discrepancies were resolved through discussion and consensus. Meta-analysis was performed using random-effects models with mean differences (MDs) for continuous outcomes on the same scale and standardized mean differences (SMDs) for outcomes using different measurement tools. Heterogeneity was assessed using the I statistic, and subgroup analyses were conducted to explore potential sources of variation. This systematic review and meta-analysis included nine trials (seven RCTs and two quasi-experimental studies) involving children and adolescents aged 0-19 years with chronic illnesses, including epilepsy, asthma, type 1 diabetes, cystic fibrosis, and leukemia. Parental involvement interventions significantly improved quality of life (SMD = 1.014; 95% CI: 0.110-1.918; p = 0.028). Subgroup analyses revealed that shorter interventions (≤ 12 weeks) were most effective (SMD = 1.676), adolescents showed moderate improvements (SMD = 0.531), and nurse-led interventions demonstrated consistent benefits (SMD = 0.737). Effects varied significantly by economic setting, with the largest improvements in lower-middle-income countries.

CONCLUSION: This study provides comprehensive evidence that parental involvement interventions significantly improve quality of life and health-related outcomes among children and adolescents with chronic illnesses, particularly when they are shorter in duration and nurse-led.

WHAT IS KNOWN: •Parental involvement is essential in managing chronic illnesses in children and adolescents. •Family-centered interventions can improve adherence, psychological well-being, and coping skills.

WHAT IS NEW: •This review and meta-analysis show that structured parental involvement interventions significantly improve quality of life, especially when short-term and nurse-led. •Findings highlight the stronger impact in lower-middle-income countries, emphasizing equity in pediatric chronic care.

**中文摘要译文：**
本研究旨在综合来自评估父母参与干预对患有慢性病的儿童和青少年生活质量及健康结局影响的随机对照试验（RCTs）和准实验研究的证据。两名独立评审员根据预设的纳入标准，在六个数据库（PubMed/MEDLINE、Scopus、ScienceDirect、Cochrane Library和Embase）中筛选研究。分歧通过讨论和共识解决。荟萃分析采用随机效应模型进行，对于使用相同量表的连续性结局采用均数差（MDs），对于使用不同测量工具的结局则采用标准化均数差（SMDs）。异质性通过I²统计量进行评估，并进行亚组分析以探究潜在的变异来源。本系统综述和荟萃分析纳入了九项试验（七项RCTs和两项准实验研究），涉及年龄在0-19岁之间、患有慢性疾病（包括癫痫、哮喘、1型糖尿病、囊性纤维化和白血病）的儿童和青少年。父母参与干预显著改善了生活质量（SMD = 1.014; 95% CI: 0.110-1.918; p = 0.028）。亚组分析显示，较短的干预（≤ 12周）效果最显著（SMD = 1.676），青少年群体表现出中度改善（SMD = 0.531），而由护士主导的干预显示出持续的益处（SMD = 0.737）。干预效果因经济背景而异，在中低收入国家改善最为显著。

结论：本研究提供了全面的证据，表明父母参与干预能显著改善患有慢性疾病的儿童和青少年的生活质量及健康相关结局，特别是当干预持续时间较短且由护士主导时。

已知信息： • 父母参与对于管理儿童和青少年的慢性疾病至关重要。 • 以家庭为中心的干预可以改善治疗依从性、心理健康和应对技巧。

新发现： • 本系统综述和荟萃分析表明，结构化的父母参与干预能显著提高生活质量，尤其是在短期和由护士主导的情况下。 • 研究结果突显了干预在中低收入国家中具有更强的影响，强调了儿科慢性病护理中的公平性问题。

### 第二部分 AI 大师评价

该研究通过系统综述和荟萃分析的方法，量化评估了父母参与干预对慢性病患儿及青少年生活质量的积极影响。其核心发现指出，短期（≤12周）且由护士主导的干预措施效果尤为显著，尤其是在中低收入国家。本研究的创新价值在于，它不仅证实了父母参与的重要性，更精确地指出了高效干预方案的关键特征，为优化临床实践和制定儿科慢性病管理策略提供了高质量的循证医学证据，并强调了在全球不同经济背景下实施干预的公平性问题。

---

速递结束，祝您工作愉快！